BSX Boston Scientific
PFA-and-Watchman compounder with margin room still to run; at $42, the market prices it like a plain med-tech.
⚠ defaulted drivers: horizon
The story
Boston Scientific is a diversified med-tech leader whose growth engine is electrophysiology (Farapulse pulsed-field ablation) and structural heart (Watchman), with steady contributions from endoscopy, urology and neuromodulation. Its moat is clinical data, physician training and switching costs in procedure-driven categories, refreshed by a disciplined tuck-in M&A program. It is in late high growth, compounding at mid-teens organically as PFA adoption broadens, and should slow toward a mature, high-single-digit and then GDP-like grower over the next decade.
Year-one growth of 12% sits below the 16.5% five-year CAGR because the Farapulse share gains are already in the base and competing PFA products are arriving. GAAP margin rises from about 20% toward 26% as amortization rolls off and mix and operating leverage improve, which puts it near peers like Stryker and below the adjusted margin of about 28%. The reported sales-to-capital of 0.58 is weighed down by acquisition goodwill, so I use 1.2 to reflect organic incremental reinvestment plus ongoing tuck-in deals.
Value drivers
| Revenue growth (Y1) | 12.0% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 26.0% |
| Years to target margin | 6 |
| Sales-to-capital | 1.20 |
| Beta | 0.90 |
| Failure probability | 1.0% |
| Cost of capital (WACC) | 8.8% |
| Terminal WACC | 9.1% |
Valuation bridge
| PV of explicit FCFF | 31.25B |
| PV of terminal value | 49.23B |
| Equity value | 70.18B |
| ÷ shares → per share | $48.43 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 23.09B | 12.0% | 20.9% | 4.12B | 2.06B | 2.06B | 1.90B |
| 2 | 25.64B | 11.1% | 21.9% | 4.80B | 2.13B | 2.68B | 2.26B |
| 3 | 28.23B | 10.1% | 22.9% | 5.53B | 2.16B | 3.37B | 2.62B |
| 4 | 30.82B | 9.2% | 24.0% | 6.31B | 2.16B | 4.15B | 2.97B |
| 5 | 33.36B | 8.2% | 25.0% | 7.12B | 2.11B | 5.01B | 3.29B |
| 6 | 35.78B | 7.3% | 26.0% | 7.95B | 2.02B | 5.93B | 3.58B |
| 7 | 38.05B | 6.3% | 26.0% | 8.45B | 1.89B | 6.56B | 3.65B |
| 8 | 40.10B | 5.4% | 26.0% | 8.91B | 1.71B | 7.20B | 3.68B |
| 9 | 41.88B | 4.4% | 26.0% | 9.30B | 1.49B | 7.82B | 3.67B |
| 10 | 43.35B | 3.5% | 26.0% | 9.63B | 1.22B | 8.41B | 3.63B |
Key risks
- PFA competition from Medtronic, J&J and Abbott compresses Farapulse share and pricing
- Watchman growth slows if clinical data or reimbursement turn less favorable (e.g., OPTION/CHAMPION follow-through)
- Acquisition overpayment or integration missteps erode returns on capital
Catalysts
- Farapulse label expansions (persistent AF, first-line) and international PFA ramp
- Watchman concomitant-procedure adoption and next-generation device launches